DECENTRALIZED TRIAL (DCT) TECHNOLOGY INSIGHTS
-
Can DCTs Be Both Patient Centric And Financially Efficient For Sites?
While DCTs have the potential to provide more convenience and improved access for patients, the anticipated cost savings touted for these trials have yet to materialize fully at the site level. In fact, the opposite has occurred in some instances.
-
Advancing Rare Disease Research With Patient Registries
In this Q&A, “Rare dad” Harsha Rajasimha, Ph.D. of IndoUSrare discusses the current state of rare disease research and explains how patient registries can help propel drug development for rare disease therapies.
DCT TECHNOLOGY RESOURCES
-
Given study decentralization and the many electronic sources of data now available, it is time for sponsors and contract research organizations to face the inevitable: EDCs need to be “sunsetted.”
-
Learn how an eCOA tool can provide patients a chance to be heard while giving sponsors quantitative and qualitative data to track the efficacy of a treatment.
-
Read how a global medical device company was able to unlock new efficiencies by implementing data collection via electronic patient-reported outcome assessments.
-
Dive into considerations when deciding on the best COAs to implement as well as best practices when developing your eCOA strategy in this blog.
-
The rapid development of Covid-19 vaccines may lead more drug developers to increase their speed and agility by adopting electronic Trial Master File (eTMF) systems. In the case of Covid-19 vaccines, discover how eTMF systems tell a dramatic tale.
-
Download the available infographic to discover how collecting ePRO & eObsRO data via interview mode can be recommended in specific circumstances.
-
DCTs are complex, and disconnects between sites and solution providers are common. However, a dedicated site management team improves relationships between providers and sites to maximize DCTs’ value.